BRPI0515935A - pirimidinas heterociclil - ou 5-carbo substituìdas para inibição de hiv - Google Patents

pirimidinas heterociclil - ou 5-carbo substituìdas para inibição de hiv

Info

Publication number
BRPI0515935A
BRPI0515935A BRPI0515935-0A BRPI0515935A BRPI0515935A BR PI0515935 A BRPI0515935 A BR PI0515935A BR PI0515935 A BRPI0515935 A BR PI0515935A BR PI0515935 A BRPI0515935 A BR PI0515935A
Authority
BR
Brazil
Prior art keywords
alkyl
amino
optionally substituted
substituted
halo
Prior art date
Application number
BRPI0515935-0A
Other languages
English (en)
Inventor
Jerome Emile George Guillemont
Jan Heeres
Paulus Joannes Lewi
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0515935A publication Critical patent/BRPI0515935A/pt
Publication of BRPI0515935B1 publication Critical patent/BRPI0515935B1/pt
Publication of BRPI0515935B8 publication Critical patent/BRPI0515935B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"PIRIMIDINAS HETEROCICLIL- OU 5-CARBO SUBSTITUìDAS PARA INIBIçãO DE HIV". Inibidores de replicação de HIV da fórmula (I), N-óxidos, sais de adição farmaceuticamente aceitáveis, aminas quaternárias ou formas estereoisoméricas dos mesmos, em que: - a¬1¬ = a¬2¬ - a¬3¬ = a¬4¬ é -CH=CH=CH=CH-, -N=CH-CH=CH, -N=CH-N=CH-, -N=CH-CH=N, -N=N-CH=CH; -b¬1¬ = b¬2¬ - b¬3¬ = b¬4¬ é -CH=CH-CH=CH, -N=CH-CH=CH, -N=CH-N=CH, -N=CH-CH=N-, -N=N-CH=CH, -N=CH-CH=CH, -N=CH-N=CH, -N=CH-CH=N-, -N=N-CH=CH-; R¬1¬ é hidrogênio; arila; formila; C~1~ - C~6~ alquila opcionalmente substituída; C~1~ - C~6~ alquilóxicarbonila; R¬2¬ é OH; halo; C~2~-C~6~ alquinila opcionalmente substituída; carbonila substituída; carboxila; CN; nitro; amino; amino substituído; polihalometila; polihlometiltio; -S(=O)rR¬6¬; C(=NH)R¬6¬; R¬2¬ é CN;amino; amino substituído; C~1~-C~6~ alquila opcionalmente substituída; halo; C~1-6~ alquilóxi C~1-6 alquila opcionalmente substituída; C~2-6~ alquenila ou C~2-6~alquinila opcionalmente substituída; -C(=N-O-R8)-C~1-4~alquila; R¬7¬ou -X~3~-R¬7¬; X~1~ é -NR¬1¬ -, -O-, -C(=))-, CH~2~, -CHOH-, S-, -S(=O)-; R¬3¬ é CN; amino; C~1~- C~6~alquila opcionalmente substituida; -C(=N-O-R¬8¬)-C~1-4~alquila; R¬7¬; -X~3~-R¬7¬; R¬4¬ é halo; OH; C~1-6~alquila opcionalmente substituida; C~2-6~alquenila ou C~2-6~alquinila; C~3-7~ cicloalquila; C~1-6~alquilóxi; CN; nitro; polihalo C~1-6~alquila; polihalo C~1-6~alquilóxi; carbonila substituída; formila; amino; mono- ou di(C~1-4~ alquil)amino ou R¬7¬; R¬5¬ é -Y-C~q~H~2q~-L ou C~q~H~2q~-Y-C~2~H~2~r-L; L é anila ou Het; processos para o preparo desses compostos, composições farmacêuticas compreendendo esses compostos como ingredientes ativo e o uso desses compostos para a prevenção ou tratamento de infecção pelo HIV.
BRPI0515935A 2004-09-30 2005-09-29 pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica BRPI0515935B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104814 2004-09-30
PCT/EP2005/054931 WO2006035068A2 (en) 2004-09-30 2005-09-29 Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines

Publications (3)

Publication Number Publication Date
BRPI0515935A true BRPI0515935A (pt) 2008-08-12
BRPI0515935B1 BRPI0515935B1 (pt) 2019-11-19
BRPI0515935B8 BRPI0515935B8 (pt) 2021-05-25

Family

ID=34929640

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515935A BRPI0515935B8 (pt) 2004-09-30 2005-09-29 pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica

Country Status (17)

Country Link
US (1) US7531548B2 (pt)
EP (1) EP1797048B1 (pt)
JP (1) JP5162245B2 (pt)
KR (1) KR20070057798A (pt)
CN (1) CN101031550B (pt)
AR (1) AR050970A1 (pt)
AT (1) ATE520672T1 (pt)
AU (1) AU2005288865B2 (pt)
BR (1) BRPI0515935B8 (pt)
CA (1) CA2573976C (pt)
ES (1) ES2371924T3 (pt)
IL (1) IL180760A (pt)
MX (1) MX2007003798A (pt)
RU (1) RU2403244C2 (pt)
TW (1) TW200626560A (pt)
WO (1) WO2006035068A2 (pt)
ZA (1) ZA200702655B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
JP5046943B2 (ja) * 2004-09-30 2012-10-10 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性５−置換ピリミジン
WO2006035067A2 (en) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN101405283B (zh) 2006-03-30 2014-06-18 泰博特克药品有限公司 Hiv抑制性5-酰氨基取代的嘧啶类化合物
ES2353725T3 (es) * 2006-03-30 2011-03-04 Tibotec Pharmaceuticals Pirimidinas sustituidas con 5-(hidroximetileno y aminometileno) que inhiben el vih.
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
AU2007341227C1 (en) * 2006-12-29 2013-08-29 Janssen Sciences Ireland Uc HIV inhibiting 6-substituted pyrimidines
AU2007341228B2 (en) * 2006-12-29 2013-04-18 Janssen Sciences Ireland Uc HIV inhibiting 5,6-substituted pyrimidines
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
EP2635284B1 (en) 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
BR112014022790B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
CA2866852C (en) 2012-03-15 2020-12-29 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
PE20242348A1 (es) 2020-02-19 2024-12-16 Pharmasyntez Agentes antivirales para el tratamiento y la prevencion de la infeccion por vih
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
KR102939283B1 (ko) * 2022-05-03 2026-03-13 한국화학연구원 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2024103400A1 (zh) * 2022-11-18 2024-05-23 水木未来(北京)科技有限公司 作为gpr75激活剂的多环化合物、包含其的药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
EA002973B1 (ru) * 1998-03-27 2002-12-26 Янссен Фармацевтика Н.В. Производные пиримидина в качестве ингибиторов репликации вируса иммунодефицита человека
KR100643419B1 (ko) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체
SK287270B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
AU783981C (en) 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
US6989385B2 (en) * 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用

Also Published As

Publication number Publication date
TW200626560A (en) 2006-08-01
RU2007116161A (ru) 2008-11-10
ES2371924T3 (es) 2012-01-11
WO2006035068A3 (en) 2006-08-31
EP1797048B1 (en) 2011-08-17
AR050970A1 (es) 2006-12-06
ATE520672T1 (de) 2011-09-15
BRPI0515935B8 (pt) 2021-05-25
MX2007003798A (es) 2007-04-23
JP2008514680A (ja) 2008-05-08
CN101031550B (zh) 2015-05-27
AU2005288865A1 (en) 2006-04-06
CA2573976C (en) 2014-04-29
US20070208022A1 (en) 2007-09-06
IL180760A0 (en) 2007-06-03
RU2403244C2 (ru) 2010-11-10
JP5162245B2 (ja) 2013-03-13
EP1797048A2 (en) 2007-06-20
ZA200702655B (en) 2008-09-25
BRPI0515935B1 (pt) 2019-11-19
AU2005288865B2 (en) 2012-07-19
IL180760A (en) 2013-02-28
CA2573976A1 (en) 2006-04-06
CN101031550A (zh) 2007-09-05
KR20070057798A (ko) 2007-06-07
US7531548B2 (en) 2009-05-12
WO2006035068A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
BRPI0515935A (pt) pirimidinas heterociclil - ou 5-carbo substituìdas para inibição de hiv
BRPI0517272A (pt) derivados de pirimidina bicìclicos de inibição de hiv
BRPI0516746A (pt) 5-heterociclil pirimidinas para inibição de hiv
PT880508E (pt) Derivados de quinazolina como inibidores de vegf
BRPI0407741A (pt) pirimidinas e triazinas de inibição de replicação de hiv
CA2263319A1 (en) Quinazoline derivatives and pharmaceutical compositions containing them
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
PT892793E (pt) Derivados 2-cianoiminoimidazolo inibidores da pde iv
BR0211171A (pt) Compostos quìmicos
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
TW200612946A (en) Combinations of substituted 1-phenyl-1,5-dihydro-pyrido-[3,2-b]indol-2-ones and other HIV inhibitors
MY138996A (en) 4-amino-5-cyanopyrimidine derivatives
DK1330456T3 (da) N8,N13-disubstituerede quino[4,3,2-KL]acridiniumsalte som terapeutiske midler
WO2002080918A1 (en) Remedial or prophylactic agent for frequent urination or urinary incontinence
EP1747200B8 (en) Alkaloid compounds and their use as anti-malarial drugs
SE0102867D0 (sv) Non-nucleoside reverse transcriptase inhibitors
BRPI0511144A (pt) combinações de 1-fenil-1,5-diidro-pirido-[3,2-b]indol-2-onas substituìdas e outros inibidores de hiv
TNSN06441A1 (en) Use of phenylethanolaminotetralines for preparing anxiolytic drugs

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2690 DE 26-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.